2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1216

The Relationship Between Serum Homocysteine, Uric Acid and Renal Function in Chronic Gouty Patients: 2 Year Follow-up Results
Abstract Number: 1120

The Relationship Between Tender Points and Disease Severity in Patients with Fibromyalgia
Abstract Number: 1711

The Relationship Between Vascular Biomarkers and Disease Characteristics in Systemic Sclerosis: Elevated MCP-1 Is Associated with Predominantly Fibrotic Manifestations
Abstract Number: 2851

The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis
Abstract Number: 2713

The Relationship of Patient Reported Skin Symptoms to the Scleroderma HAQ, the Modified Rodnan Skin Score and Skin Pathology.
Abstract Number: 217

The Relationship of Quadriceps and Hamstrings Intramuscular Fat and Lean Muscle with Power in Women with Knee Osteoarthritis
Abstract Number: 2892

The Relative Risk of Incident NON-Ischemic Heart Failure in Prevalent Rheumatoid Arthritis
Abstract Number: 1666

The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Abstract Number: 2288

The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis
Abstract Number: 3013

The Reserve Capacity Model in Patients with Rheumatoid Arthritis: Understanding the Relationship of Socioeconomic Status, Psychosocial Resources, Mood, and Pain
Abstract Number: 2957

The Rheumatoid Arthritis -Risk Locus CCR6 and Its SNP-Dependent Response to Estrogen: A Possible Genomic Link Between Sex Hormones and the IL-17 Inflammatory Pathway
Abstract Number: 356

The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Abstract Number: 47

The Risk of Aplastic Anemia and Pancytopenia with Colchicine: A Retrospective Study of Integrated Health System Database
Abstract Number: 845

The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Abstract Number: 1624

The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].